Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa

Indira Govender,1,6 Aaron S. Karat,1 Stephen Olivier,2 Kathy Baisley,1,5 Peter Beckwith,1,4 Njabulo Dayi,2 Jaco Dreyer,3 Dickman Gareta,1,6 Resign Gunda,1,6 Karina Kielmann,1 Olivier Koole,1,3 Ngcobo Mlhongo,5 Thshwaranganang Modise,2 Sashen Moodley,2 Xolile Mpofo,3 Thumbi Ndung’u,3 Deenan Pillay,1,4 Mark J. Siedner,6,8 Theresa Smit,1 Ashmika Surujdeen,2 Emily B. Wong,6,9,10 and Alison D. Grant,1,2,11,12, for the Umoya Omuhle Teams and Vukuzazi Study Teams

1TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom; 2Clinical Research Department, Africa Health Research Institute, Somkhele, South Africa; 3Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom; 4Department of Medicine, University of Cape Town, Cape Town, South Africa; 5School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; 6Institute for Global Health and Development, Queen Margaret University, Edinburgh, United Kingdom; 7School of Public Health, Harvard Medical School, Boston, Massachusetts, USA; 8Division of Infection and Immunity, University College London, London, United Kingdom; 9Division of Infectious Diseases, University of Alabama Birmingham, Birmingham, Alabama, USA; 10School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and 11School of Public Health, University of the Witwatersrand, Johannesburg, South Africa

Background. Tuberculosis (TB) case finding efforts typically target symptomatic people attending health facilities. We compared the prevalence of Mycobacterium tuberculosis (Mtbt) sputum culture-positivity among adult clinic attendees in rural South Africa with a concurrent, community-based estimate from the surrounding demographic surveillance area (DSA).

Methods. Clinic: Randomly selected adults (≥18 years) attending 2 primary healthcare clinics were interviewed and requested to give sputum for mycobacterial culture. Human immunodeficiency virus (HIV) and antiretroviral therapy (ART) status were based on self-report and record review. Community: All adult (≥15 years) DSA residents were invited to a mobile clinic for health screening, including serological HIV testing; those with ≥1 TB symptom (cough, weight loss, night sweats, fever) or abnormal chest radiograph were asked for sputum.

Results. Clinic: 2055 patients were enrolled (76.9% female; median age, 36 years); 1479 (72.0%) were classified HIV-positive (98.9% on ART) and 131 (6.4%) reported Mtb culture-positive sputum, 45 (77.6%) reported no symptoms. In both surveys, sputum culture positivity was associated with male sex and reporting >1 TB symptom.

Conclusions. In both clinic and community settings, most participants with Mtbt culture-positive sputum were asymptomatic. TB screening based only on symptoms will miss many people with active disease in both settings.

Keywords. culture-positive; prevalence; South Africa; sputum; tuberculosis.

South Africa is a high tuberculosis (TB)-burden country with a human immunodeficiency virus (HIV)-driven epidemic [1]. The most recent estimated incidence rate is approximately 615 per 100 000 per year; 58% of all people with TB are living with HIV [2]. While increased access to antiretroviral therapy (ART) has contributed to improved TB prevention and care, TB remains the leading cause of death in South Africa [3, 4]. Tuberculosis case finding policy in most high-TB prevalence settings recommends routine symptom screening of all adult clinic attendees and testing those who self-present with TB symptoms (cough of any duration, night sweats, loss of weight, or fever) [5, 6]. However, difficulties with facility-based case finding result in delays and missed opportunities for case detection [7–10].

Despite broad access to Xpert MTB/RIF and more recently Xpert MTB/RIF Ultra (Cepheid), the national TB prevalence in South Africa was estimated to be 737 per 100 000 in 2018 [11]. Given the impact of the coronavirus disease 2019 (COVID-19) pandemic on TB detection, there is a clear need for earlier identification and treatment of people with active TB [2, 12]. We conducted a survey at 2 primary healthcare clinics (PHCs) in KwaZulu-Natal, South Africa, within the Africa Health Research Institute (AHRl) demographic surveillance area (DSA) [13], to estimate the prevalence of Mycobacterium tuberculosis (Mtbt) culture-positive sputum among adult clinic attendees.
the same period, a population-wide, community-based survey was being conducted in the DSA that included screening and testing adults for TB [14]. In this analysis we compared the prevalence of sputum culture-positivity between individuals attending clinics for ambulatory care and individuals in the surrounding community.

METHODS

Ethics Statement
The ethics committees of the University of KwaZulu-Natal and the London School of Hygiene and Tropical Medicine granted approval for both surveys. The Partners Human Research Committee Institutional Review Board of Partners HealthCare in the United States approved the community-based survey. Data linkage was conducted under ethics approval for the AHRI DSA [13].

All enrolled participants gave written consent or witnessed verbal consent for those who could not read or write.

Study Design

Clinic Survey
In a cross-sectional study between June 2018 and May 2019, adults (aged ≥18 years) attending for healthcare were randomly selected from 2 PHCs in the Hlabisa subdistrict of uMkhanyakude, using AHRI’s electronic patient registration system as a sampling frame [15]. Exclusion criteria included attending for an emergency visit, being in labor, previous participation in the survey, or attending on behalf of a patient. Consenting adults completed a questionnaire focused on their reason for clinic attendance, TB history, and presence or absence of TB symptoms (as defined above), or any other symptoms (as an open question). Midupper arm circumference (MUAC) was measured, with a cutoff of less than 24 cm as a proxy indicator of low body mass index (BMI) [16]. Participants confidentially recorded their HIV and ART status on the digital tablet provided. All participants were asked to produce a single sputum specimen, which was sent to the AHRI Research Diagnostic Laboratory for culture in liquid media using the Mycobacteria Growth Indicator Tube system (MGIT; Becton Dickinson Microbiology Systems) and phenotypic drug sensitivity testing (DST) using the solid agar 1% proportion method for Mtb complex. Any participant who reported having 1 or more TB symptom was asked to provide a second sputum specimen for testing in the public health system using Xpert MTB/RIF Ultra (Xpert Ultra; Cepheid). Participants’ clinic files were reviewed for evidence of HIV and TB testing and treatment within the 12-week period after enrollment. Additional details on the survey design, participant selection, and laboratory procedures are provided in Supplementary Methods.

Community Survey
During the baseline data collection period, 36 097 AHRI DSA resident adults (aged ≥15 years) were eligible for enrollment. Individuals were invited to participate in a mobile screening and multi-disease testing camp that moved through the study area [14]. We report on participants who enrolled in the first 12 months of the community survey, contemporaneous with the clinic survey. As part of a comprehensive health and treatment history, all enrolled participants were screened for TB symptoms, had a MUAC measurement taken, and unless pregnant, a digital chest radiograph, which was analyzed using version 5 of the computer-aided detection for TB (CAD4TB; Thirona, Netherlands) software [17]. Participants who reported 1 or more TB symptom, had a CAD4TB score of greater than 60 (between May and September 2018) or greater than 25 (from October 2018 onwards), or were pregnant were asked to produce sputum. The sputum specimen was divided into 2 portions in the AHRI laboratory: 1 portion was tested using Xpert Ultra and the other was cultured on MGIT. Positive cultures underwent first-line DST. All participants had blood drawn for HIV testing (Genscreen Ultra HIV Ag-Ab enzyme immunoassay; Bio-Rad). Participants with a positive HIV immunoassay had a reflex HIV-1 RNA viral load performed (Abbott RealTime HIV-1 Viral Load; Abbott, USA).

In both studies, participants’ results were reviewed by a study clinician and participants were contacted and referred to care and treatment as appropriate.

Study Outcomes
The primary outcome for this analysis was a sputum positive for Mtb on liquid culture. Participants who were unable to produce a sputum specimen were considered sputum culture negative. Only Mtb culture-positive cases from the community survey were compared with those in the clinic survey. A secondary analysis including Xpert Ultra results is described further in the Supplementary Methods and HIV/ART status in Supplementary Table 1.

Data Management and Statistical Considerations
Data were captured electronically using Research Electronic Data Capture (REDCap) tools (Vanderbilt University) hosted at AHRI [18, 19]. Data entry for both studies was done using encrypted Android tablets. Data were analyzed using Stata/IC 15.1 (StataCorp, USA) and R 3.5.0 [20].

The sample size for the clinic survey was based on a precision estimate, assuming the prevalence of TB in the general population was 1.5% [21], and among PHC attendees to be around 3%. To allow for estimation of an overall TB prevalence of 3% with a precision of ±0.8%, the study aimed to enroll 3400 adult attendees (1700 per clinic) to obtain the target sample size of 2000 participants with a sputum sample, assuming that 60% could produce a specimen. No formal sample size calculations were done for the community survey, since all resident adults were eligible to participate. However, the first 10 000 participants
permitted estimation of a prevalence of \textit{Mtb}-positive sputum of 1\% with a precision of ±0.2\%.

The prevalence of culture-confirmed \textit{Mtb} and its 95\% confidence interval (CI) were calculated for each survey. The Supplementary Methods describe the sensitivity analysis, data linkage for the clinic survey, and risk factor analysis for both surveys.

RESULTS

Clinic Survey

Between 25 June 2018 and 21 May 2019, 3506 of 7333 patients were electronically sampled and 243 were manually sampled, giving a total 3749 patients. Following screening and consent procedures, 2055 participants were enrolled into the study (Figure 1), which was fewer than originally intended because the study started later than planned. Supplementary Figure 1 illustrates the full enrollment cascade. Supplementary Table 2 compares characteristics of participants and nonparticipants among those sampled and eligible to participate, based on data linkage methods.

Among the 2055 participants enrolled, the median age was 36 (interquartile range [IQR], 28–48) years and 76.9\% were female (Table 1). A total of 1479 (72\%) participants were classified as HIV-positive, of whom 1463 (98.9\%) were taking ART. A total of 1189 (80\%) of those classified as HIV-positive reported visiting the clinic for HIV care on the day of enrollment. A total of 505 of 2055 (24.6\%) participants reported past TB treatment, 14 of 2055 (0.7\%) reported current TB treatment, and 131 of 2055 (6.4\%) reported having 1 or more TB symptom at enrollment.

A total of 1035 of 2055 (50.4\%) participants produced a sputum specimen, of which 47 were contaminated; 988 specimens were included in analysis. Twenty participants gave a sputum specimen that grew \textit{Mtb}, giving a prevalence of 1.0\% (95\% CI, 0.6–1.5; 973 [95\% CI, 630–1050] per 100 000) (Figure 1), which was not substantially altered (1.0\% [95\% CI, 0.6–1.5]; 990 [95\% CI, 640–1054] per 100 000) after adjusting for nonresponse (Supplementary Table 4).

Among the 20 participants with a positive \textit{Mtb} sputum culture, the median age was 37 years and 9 (45.0\%) were male (Table 2). Thirteen of 20 participants (60.0\%) reported having no history of TB, 15 of 20 (75.0\%) were classified as HIV-positive (all on ART), and 6 of 20 (30.0\%) reported having 1 or more TB symptom. Four (25.0\%) \textit{Mtb} isolates were found to be multidrug-resistant (resistant to rifampicin and isoniazid) and 1 (5.0\%) mono-resistant to rifampicin. Three (60.0\%) out of 5 sputum specimens with drug-resistant isolates were collected from participants who reported being previously treated for TB. All 20 participants with culture-positive sputum had...
further sputum tests at varying time points over the course of their care in the public health service, of which 12 were positive (Supplementary Table 5).

Community Survey

Between 24 May 2018 and 25 May 2019, research teams visited 3195 households in the DSA and attempted to contact 19 157 individuals, 15 234 of whom were successfully contacted and invited to participate in the community survey (Figure 1). Of these, 578 declined and a further 4336 did not attend the mobile camps, leaving a total 10 320 enrolled participants. Of these, 6481 were asked to give a sputum specimen based on reporting 1 or more TB symptom (n = 1091), having a CAD4TB score above the study threshold (n = 5491), or being pregnant (n = 328) (Supplementary Table 3).

Among the 10 320 enrolled participants, the median age was 38 years, 68.3% were female, 3105 tested HIV-positive, and 2714 (87.4%) were on ART (Supplementary Table 3). A total of 1228 of 10 320 (11.9%) reported past TB treatment, and 1091 of 10 320 (10.6%) reported having 1 or more TB symptom at enrollment. A total of 5274 of 10 320 produced sputum specimens, of which 420 were contaminated, leaving 4854 included in the analysis. Fifty-eight sputum specimens cultured Mtb on liquid media, giving a prevalence of 0.6% (95% CI 0.4–0.7%); 562 (95% CI, 420–710) per 100 000 (Figure 1), which remained the same after adjusting for nonresponse (0.6% [95% CI, 0.4–0.7%]; 562 [95% CI, 430–740] per 100 000). In addition, 20 participants had sputum specimens that were culture negative but Xpert Ultra positive (greater than trace).

Of the 58 participants with a positive Mtb sputum culture, the median age was 48 years and 28 (48.0%) were male (Table 2). Forty-eight of 58 participants (82.2%) reported having no history of TB, 26 of 58 (44.8%) were HIV-positive, and 21 of 26 (80.8%) were taking ART. Nine (15.5%) Mtb isolates were found to be multidrug-resistant and 2 (3.4%) were mono-resistant to rifampicin. Two (18%) out of 11 sputum specimens with drug-resistant isolates were from participants who reported previous TB treatment. The median age in the Xpert Ultra positive–only group was 53 years and 12 (60.0%) were male. Five of 20 participants (20.0%) reported having no history of TB, 10 of 20 (50.0%) were HIV-positive, and 9 of 10 (90%) were on ART. Rifampicin resistance was detected in 2 (10.0%) of these specimens; 1 of the 2 specimens was from a participant who reported previous treatment for TB.

The effects of including Xpert Ultra–positive and trace-positive results on study outcomes are described in Supplementary Results and Supplementary Table 4.

Associations With Mtb Culture-Positive Sputum

In a univariable analysis of the clinic survey data (Table 3), Mtb sputum culture positivity was associated with TB symptoms (odds ratio [OR], 8.6 [95% CI, 3.0–24.6], P < .001 for >1 TB symptom vs none; OR, 3.0 [95% CI, 1.4–23.0], P = .299, for 1 TB symptom vs none) and male sex (OR, 2.8 [95% CI, 1.1–6.7]; P = .024).

In the community survey (Table 4) male sex (OR, 2.0 [95% CI, 1.2–3.4]; P = .008), age older than 44 years (vs 15–24 years; OR, 2.5 [95% CI, 1.2–5.9]; P = .02), being HIV-positive on ART (vs HIV-negative; OR, 1.9 [95% CI, 1.1–3.2]; P = .024), having a MUAC of less than 24 cm (vs ≥24 cm; OR, 3.2 [95% CI, 1.7–5.7]; P < .001), and reporting 1 or more TB symptom (vs none; OR, 4.5 [95% CI, 1.9–9.0]; P < .001) were associated with sputum culture positivity; results were little changed after weighting for nonresponse. In a multivariable analysis (Table 4),
male sex (OR, 2.4 [95% CI, 1.4–4.0]; *P* = .001), age older than 44 years (vs 15–24 years; OR, 2.7 [95% CI, 1.3–6.3]; *P* = .016), and being HIV-positive on ART (vs HIV-negative; OR, 2.0 [95% CI, 1.1–3.5]; *P* = .022) remained independently associated with sputum culture positivity.

**DISCUSSION**

We present simultaneous estimates of the prevalence of *Mtb* culture-positive sputum among ambulatory clinic attendees and adults in the surrounding community. Based on culture results only, the prevalence among clinic attendees was slightly higher compared to the community. Further, demographic and clinical characteristics were associated with culture positivity.

### Table 2. Characteristics of Enrolled Participants Who Were Sputum Culture Positive and/or Sputum Xpert Ultra Positive for *Mycobacterium tuberculosis*: Clinic and Community Survey

| Characteristics                  | MGIT Positive Only | Xpert Ultra Positive Only |
|----------------------------------|-------------------|---------------------------|
|                                  | Clinic (n = 20)   | Community (n = 58)        | Community (n = 20) |
| Age, median (IQR), y             | 37 (32-48)        | 48 (30-64)                | 53 (43-60)        |
| Male, n (%)                      | 9 (45.0)          | 28 (48.0)                 | 12 (60.0)         |
| MUAC, median (IQR), cm           | 25.6 (23.9-26.0)  | 27.0 (24.0-30.0)          | 28.0 (26.0-30.0)  |
| TB treatment history, n (%)      |                   |                           |                  |
| On treatment                     | 2 (10.0)          | 4 (6.9)                   | 4 (20.0)         |
| Previously treated               | 5 (25.0)          | 6 (10.3)                  | 11 (55.0)        |
| No history                       | 13 (65.0)         | 48 (82.2)                 | 5 (25.0)         |
| HIV status, n (%)                |                   |                           |                  |
| Negative                         | 5 (25.0)*         | 31 (53.4)                 | 10 (50.0)        |
| Positive                         | 15 (75.0)*        | 26 (44.8)                 | 10 (50.0)        |
| On ART                           | 15 (100.0)*       | 21 (80.8)                 | 9 (90.0)         |
| ≥1 TB symptom, n (%)             | 6 (30.0)          | 13 (22.4)                 | 3 (15.0)         |
| Rifampicin mono-resistance       | 1 (5.0)           | 2 (3.4)                   | 2 (10.0)*        |
| Multidrug resistance             | 4 (25.0)          | 9 (15.5)                  | ...              |
| Follow-up TB tests, n (%)        |                   |                           |                  |
| Positive                         | 12 (60.0)         | ...                      | ...              |
| Negative                         | 8 (40.0)          | ...                      | ...              |

**Table 3. Univariable Analysis of Clinic-Based Survey (N = 2055), Showing Factors Associated With Being Sputum Culture Positive (n = 20)**

| Characteristics                  | No. Sputum Culture Positive/No. Total Participants (%) | OR (95% CI) | *P* |
|----------------------------------|-------------------------------------------------------|-------------|-----|
| Sex                              |                                                       |             |     |
| Female                           | 11/1580 (0.7)                                         |             |     |
| Male                             | 9/472 (1.9)                                           | 2.8 (1.1–6.7) | .024 |
| Not recorded                     | 0/3                                                   |             |     |
| Age                              |                                                       |             |     |
| <25 y                            | 2/312 (0.6)                                           |             |     |
| 25-44 y                          | 12/1077 (1.1)                                         | 1.7 (1.4–7.8) | .467 |
| >44 y                            | 6/666 (0.9)                                           | 1.4 (1.3–7.0) | .676 |
| HIV status<sup>a</sup>           |                                                       |             |     |
| Negative                         | 4/537 (0.7)                                           |             |     |
| Positive                         | 15/1473 (1.0)                                         | 1.4 (0.5–4.1) | .577 |
| Unknown                          | 1/45 (2.2)                                            | 3.0 (1.3–27.7) | .326 |
| MUAC                             |                                                       |             |     |
| ≥24 cm                           | 15/1822 (0.8)                                         |             |     |
| <24 cm                           | 5/227 (2.2)                                           | 2.7 (1.0–75) | .056 |
| Not measured                     | 0/6                                                   |             |     |
| TB symptoms                      |                                                       |             |     |
| None reported                    | 13/1924 (0.7)                                         |             |     |
| Reported 1 symptom               | 1/47 (2.1)                                            | 3.0 (1.4–23.0) | .299 |
| Reported ≥2 symptoms             | 5/131 (3.8)                                           | 8.6 (3.0–24.6) | <.001 |

**Abbreviations:** ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; MGIT, Mycobacterial Growth Indicator Tube; MUAC, midupper arm circumference; TB, tuberculosis; Xpert Ultra, Xpert MTB/RIF Ultra assay (Cepheid).

<sup>a</sup>Self-report and clinical record review.

<sup>b</sup>Rifampicin resistance detected.
Table 4. Univariable and Multivariable Analysis of Community-Based Survey (N = 10,320), Showing Factors Associated With Being Sputum Culture Positive (n = 58)

| Characteristics     | No. Sputum Culture Positive/No. Total Participants (%) | Univariable Analysis |   | Multivariable Analysis |   |
|---------------------|--------------------------------------------------------|----------------------|---|------------------------|---|
|                     |                                                        | OR (95% CI)          | P | Weighted^a OR (95% CI) | P |
|                     |                                                        | P                    |   | Weighted^a OR (95% CI) | P |
| Sex                 |                                                        |                      |   |                        |   |
| Female              | 30/7049 (0.4)                                          |                      |   |                        |   |
| Male                | 28/3271 (0.9)                                          | 2.0 (1.2–3.4)        | .008 | 1.8 (1.3–2.7)        | .002 |
|                     |                                                        |                      |   |                        |   |
| Age                 |                                                        |                      |   |                        |   |
| 15–24 y             | 8/2802 (0.3)                                           |                      |   |                        |   |
| 25–44 y             | 19/3189 (0.6)                                          | 2.1 (1.0–5.1)        | .08 | 2.8 (1.6–5.2)        | <.001 |
| >44 y               | 31/4329 (0.7)                                          | 2.5 (1.2–5.9)        | .02 | 3.1 (1.8–5.7)        | <.001 |
| HIV status          |                                                        |                      |   |                        |   |
| Negative            | 31/7151 (0.4)                                          |                      |   |                        |   |
| Positive on ART     | 22/2714 (0.8)                                          | 1.9 (1.1–3.2)        | .024 | 1.7 (1.1–2.6)        | .01  |
| Positive not on ART | 4/391 (1.0)                                            | 2.4 (1.7–6.0)        | .11 | 1.8 (1.7–3.7)        | .20  |
| MUAC                |                                                        |                      |   |                        |   |
| ≥24 cm              | 44/9379 (0.5)                                          |                      |   |                        |   |
| <24 cm              | 14/941 (1.0)                                           | 3.2 (1.7–5.7)        | <.001 | 3.6 (2.3–5.4)       | <.001 |
| TB symptoms         |                                                        |                      |   |                        |   |
| None reported       | 45/9229 (0.5)                                          |                      |   |                        |   |
| Reported 1 symptom  | 5/717 (0.7)                                            | 1.4 (1.5–3.3)        | .4  | 1.3 (1.6–2.5)        | .5   |
| Reported >1 symptom | 8/334 (2.1)                                            | 4.5 (1.9–9.0)        | <.001 | 6.1 (3.6–9.7)       | <.001 |

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; MUAC, midupper arm circumference; OR, odds ratio; TB, tuberculosis.

^Weights calculated as the inverse probability of participation in the community survey based on age, sex, and previous HIV status.
than in the community, and CIs overlapped. In both surveys, most participants with culture-positive sputum did not report any symptoms, although reporting TB symptoms was associated with having culture-positive sputum. This has been reported in other community-based TB prevalence surveys [22-24] but not previously reported among adult clinic attendees. The degree of infectiousness of asymptomatic individuals with subclinical disease compared with symptomatic people is not known [25, 26]. Symptom screening as the entry point to case detection in the current model of care needs to be revisited, particularly if asymptomatic individuals are infectious.

In both surveys, the direction of the associations with risk factors was the same. HIV infection is a known risk factor for developing TB disease and, given the study setting, this finding is not unexpected [27]. HIV-positive persons taking ART attend health facilities relatively frequently, giving more opportunities for TB screening, but screening limited to those attending for HIV care will miss HIV-positive patients who attend clinics for other reasons [28]. In addition, symptom-based screening for TB has lower sensitivity among people who are HIV positive and on ART [29].

Tuberculosis prevalence estimates from previous studies based on exit interviews of only symptomatic adults attending PHCs in South Africa range between 3.6% [8] and 5% [9]. Our estimate of lower TB prevalence among clinic attendees in comparison to previous estimates is most likely a result of our attempt to construct a true random sample of adult ambulatory care attendees and to request sputum from all those enrolled, regardless of symptoms.

Our community survey screening methods are comparable to other surveys [22, 23, 30, 31], but our estimate is based on a single sputum specimen. National TB prevalence survey estimates are based on 2 specimens and our estimate is therefore likely to underestimate prevalence compared with the national survey and other surveys in which multiple samples are collected. Our community estimates are consistent with those reported in a recent study from Uganda based on a single sputum specimen tested with Xpert Ultra [24]. Including all Xpert Ultra–positive tests resulted in an estimated community prevalence of 940 (95% CI, 780–1130) per 100,000 and 420 (95% CI, 320–550) per 100,000 adults when Xpert Ultra trace-positive and culture-negative sputum results were excluded.

Our community survey aimed to enroll as many DSA residents as possible; our sample was therefore not representative, but weighting for nonresponse did not materially affect our estimate. In both surveys, men were underrepresented, which may have resulted in an underestimate of overall prevalence, since men are known to be disproportionately affected by TB [32, 33]. In the same way, our prevalence findings could be an overestimate if people who were ill were more likely to participate in the community survey, but this would not explain the high number of participants with culture-positive sputum who were asymptomatic at enrollment.

Chest radiography is the most sensitive TB screening method currently available [22, 23, 31, 34] and has the potential to substantially increase the yield of case finding in high-prevalence settings [35]. Although costly, digital chest radiography in combination with computer-aided detection software is a promising alternative in settings where limited human resources are a barrier to implementation [36].

Our analysis has the following limitations. Participation in both surveys was incomplete, but prevalence estimates were not substantially different after weighting for nonresponse. The clinic survey did not achieve its intended sample size, resulting in a less precise estimate than planned. Only 50% of clinic survey participants were able to produce a sputum sample, which may have resulted in an underestimate of the true prevalence of TB among clinic attendees. Because we did not request sputum from all participants in the community survey, we may have underestimated true prevalence. Due to logistical constraints, both surveys relied on a single sputum specimen from each participant to detect active TB, and our primary comparison is based on sputum MGIT culture only. Studies among patients being investigated for TB have estimated the incremental yield of culture-positive Mtb from a second sputum specimen to be between 6% and 10% [37, 38]. In the clinic survey, most participants with culture-positive sputum had a second specimen confirming TB disease through routine care in the public health service. Had any of the clinic survey sputum specimens been false-positive cultures, our prevalence estimate would be an overestimate, in which case the true prevalence would be closer to the community-based estimate. In addition, because of the limited number of cases, false-positive results could have biased the results of the multivariable analysis. Reliance on a single sputum specimen in the community survey could have resulted in an overestimate from false-positive results, but equally, collecting only 1 specimen may have resulted in an underestimate of true prevalence [37].

In conclusion, TB case finding based on symptom screening and restricted to health facilities will miss many people with TB disease. If individuals without symptoms, in the subclinical phase of the disease, are infectious, the existing case finding strategy will need to be reconsidered. Work towards understanding the relative contribution of asymptomatic people to TB transmission is ongoing and will be of particular importance to determine the conditions under which sympto-magnostic screening algorithms should be considered. A clear strategy is also needed to detect HIV-negative people with TB in the community. There is an urgent need for better low-cost, high-sensitivity screening tests for TB in community and clinic settings.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted...
materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Acknowledgments. The authors thank the study participants, community members, members of the community advisory board, staff in the health facilities where these studies were conducted, and the many AHRI staff who contributed to these studies, including Nkosingiphile Buthelezi, Siphephelo Dlamini, Yutu Dlamini, Anita Edwards, Patrick Gabela, Emmerence Gumede, Sashin Harilall, Kubus Herbst, Mandla Khoza, Nozi Khumalo, Zilethile Khumalo, Nondumiso Kumalo, Richard Lessells, Sithembiso Luthuli, Sinethemba Mabayukhu, Nonhlanha Madlophi, Thabile Mkhize, Duduzile Mkwanazi, Zinhle Mkwanazi, Zodwa Mkwanazi, Sihle Mthethwa, Sphiwe Mthethwa, Nozipho Mthethwa, Silindile Mthembu, Sanele Mthiyane, Vanisha Munsamy, Tenvania Naidoo, Nompiro Ndleta, Thandekile Nene, Sabelo Ntuli, Nonpumulelo Nyawo, Anandan Ramnanan, Aruna Sevakram, Siwezi Sikhakane, Zizille Sikhosana, Marlise Venter, Precious Zulu, and all the staff of the AHRI Research Diagnostic Laboratory.

Financial support. The clinic survey is part of the Umoya Oumhle program, supported by the Economic and Social Research Council (ESRC) (grant number ES/P008011/1), in partnership with the National Institute for Health Research (NIHR), Arts and Humanities Research Council (AHRC), the Medical Research Council (MRC), and the Department for Environment, Food and Rural Affairs (Defra) and the Veterinary Medicines Directorate (VMD). The community survey was supported by the Wellcome Trust via a strategic award to AHRI (grant number 201433/Z/16/A).

Potential conflicts of interest. I. G. reports salary support from the UK Economic and Social Research Council (grant awarded to the London School of Hygiene and Tropical Medicine [LSHTM]). A. S. K. reports support from The BloombergSBY (Research England) (grant awarded to their institution, London School of Hygiene & Tropical Medicine), the National Institute for Health Research (NIHR), Colt Foundation (UK), ViV Healthcare (USA), Queen Margaret University (UK), World Health Organization, Medical Research Council (UK), London School of Hygiene and Tropical Medicine (UK), and grants awarded to their employer/insti-
tution; reports consulting fees from the University of Cape Town (South Africa), South African National TB Think Tank (funded by the Bill and Melinda Gates Foundation, USA), Center for Health Policy and Studies (Republic of Moldova), Vital Strategies (Singapore; funded by Bloomberg Philanthropies, USA), The Aurim Institute (South Africa), and Edanz Group (Japan); reports travel and accommodation costs from Africa Health Research Institute (South Africa), Kyoto University (Japan), University College London (UK), Vital Strategies (Singapore), and Open Access publishing costs from the Bill and Melinda Gates Foundation (USA). K. K. reports salary support and travel expenses and support towards article-processing charges received for a role on the Umoya Oumhle project (from which the paper draws its data) from the UK Economic and Social Research Council (payments made to Queen Margaret University), grant received from the Joint Health Systems Research Initiative (Medical Research Council/Economic and Social Research Council/Department for International Development/Wellcome Trust) and a grant received from the National Institute for Health Research (NIHR; payments made to Queen Margaret University). O. K. reports salary support through grant to the institutions (Africa Health Research Institute [AHRI] and LSHTM) from Wellcome Trust (core grant 082384/Z/07/Z) and the Bill and Melinda Gates Foundation (OPP1175182). T. N. reports support from Wellcome Trust African Academy of Sciences and the South African National Research Foundation, the Bill and Melinda Gates Foundation and Max Planck Society and reports serving as member of the External Advisory Committee for HIV Vaccine Trials Network. E. B. W. reports support from Massachusetts General Hospital, the Africa Health Research Institute, University of Alabama at Birmingham, Bill and Melinda Gates Foundation, Wellcome Trust and National Institutes of Health. A. G. reports funding for other projects paid to their institution by the National Institutes of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Research England, Wellcome Trust, and Medical Research Council and reports travel support paid to their institution by Wellcome Trust and Economic and Social Research Council. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Churchyard GJ, Mameletja LD, Mvuyi L, et al. Tuberculosis control in South Africa: successes, challenges and recommendations. South African Med J 2014; 104:244-8.
2. World Health Organization (WHO). Global tuberculosis report 2020. Geneva, Switzerland: World Health Organization, 2020. Available at: https://www.who.int/publications/i/item/9789240013131. Accessed 22 October 2020.
3. Tomita A, Smith CM, Lessells RJ, et al. Space-time clustering of recently diagnosed tuberculosis and impact of ART scale-up: evidence from an HIV hyper-endemic rural South African population. Sci Rep 2019; 9:1-9.
4. Loveday M, Mzobe YN, Pillay Y, Barron P, Sa S, F. Figures of the dead: a decade of tuberculosis mortality registrations in South Africa. South African Med J 2019; 109:728-32.
5. World Health Organization. Systematic screening for active tuberculosis: princi-
plies and recommendations. Geneva, Switzerland: WHO Press, 2013.
6. South African National Department of Health. National tuberculosis management guidelines 2014. Pretoria, South Africa, 2014. Available at: https://www. knowledgehub.org/ehlibary/national-tuberculosis-management-guidelines. Accessed 27 July 2020.
7. Chihota V, Gimindza S, McCarthy K, Grant A, Churchyard G, Fielding K. Missed opportunities for TB investigation in primary care clinics in South Africa: experience from the XTEND trial. PloS One 2015; 10:e0131849.
8. Kweza PF, Van Schalkwyk C, Abraham N, Uys M, Claessens MM. Estimating the magnitude of pulmonary tuberculosis patients missed by primary health care clinics in South Africa. Int J Tuberc Lung Dis 2018; 22: 264-72.
9. Claessens MM, Jacobs E, Cyster E, et al. Tuberculosis cases missed in primary health care facilities: should we redefine case finding? Int J Tuberc Lung Dis 2013; 17:608-14.
10. Christian CS, Gerdiham UG, Hompashe D, Smith A, Burger R. Measuring quality gaps in TB screening in South Africa using standardised patient analysis. Int J Environ Res Public Health 2018; 15:729.
11. Van der Walt M, Moyo S. The First National TB Prevalence Survey, South Africa 2018: short report. 2021. Available at: https://www.knowledgehub.org.za/system/files/ebiddownloads/2021-02/A4_SA_TPS%20Short%20Report_10June20_Final_highres.pdf. Accessed 11 October 2021.
12. Zhou S, Van Staden Q, Tisoka E. Resource reprisalisation amid competing health risks for TB and COVID-19. Int J Tuberc Lung Dis 2020; 24:1215-6.
13. Gareta D, Baisley K, Mngomezulu T, et al. Cohort profile update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 2020; 50:33-4.
14. Wong EB, Olivier S, Gunda R, et al. Convergence of infectious and non-
communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob Health 2021; 9:9-11.
15. Baisley PE, Sedey J, Siedner M, et al. Findings from home-based HIV testing and facilitated linkage after scale up of test and treat in rural South Africa: young people still missing. HIV Med 2019; 20:704-8.
16. Tang AM, Chung M, Dong KR, et al. Determining a global mid-upper arm circumference cut-off to assess underweight in adults (men and non-pregnant women). Washington, DC: FHI 360/FANTA, 2020.
17. Febr J, Konioski S, Olivier S, et al. Computer-aided interpretation of chest radiography to detect TB in rural South Africa. NPI Digital Med 2021; 4:106.
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research elec-
tronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:577-81.
19. Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: building an inter-national community of software platform partners. J Biomed Inform 2019; 95:103208.
20. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
21. Ayles H, Muoyeta M, Du Toit E, et al. Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet 2013; 382:1183-94.
22. Nguyen HV, Tiemersma EW, Nguyen HB, et al. The second national tuberculosis prevalence survey in Vietnam. PLoS One 2020; 322:1-15.
23. Enos M, Sitenei J, Ong’ang’o J, et al. Kenya Tuberculosis Prevalence Survey 2016: challenges and opportunities of ending TB in Kenya. PLoS One 2018; 13:e02099981-19.
24. Kendall EA, Kitonsa PJ, Nalutaaya A, et al. The spectrum of tuberculosis disease in an urban Ugandan community and its health facilities. Clin Infect Dis 2020; 72:e1035-43.

25. Turner RD, Chiu C, Churchyard GJ, et al. Tuberculosis infectiousness and host susceptibility. J Infect Dis 2017; 216:5636-43.

26. Wong EB. It is time to focus on asymptomatic tuberculosis. Clin Infect Dis 2020; 72:e1044-6.

27. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med 2013; 2013:828939.

28. Safari W, Randera-Rees S, Madolo T, et al. Can we find the missing men in clinics? Clinic attendance by sex and HIV status in rural KwaZulu-Natal, South Africa. Presented at: TB Science, 49th Union World Conference on Lung Health; The Hague, The Netherlands, 24-27 October 2018.

29. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV 2016; 5:e51-23.

30. Kapata N, Chanda-Kapata P, Ngosa W, et al. The prevalence of tuberculosis in Zambia: results from the first national TB prevalence survey, 2013-2014. PLoS One 2016; 11:e0146392.

31. Migambi P, Gasana M, Uwizeye CB, et al. Prevalence of tuberculosis in Rwanda: results of the first nationwide survey in 2012 yielded important lessons for TB control. PLoS One 2020; 11:e1-12.

32. Kigozi G, Engelbrecht M, Heunis C, Rensberg AJV. Household contact non-attendance of clinical evaluation for tuberculosis: a pilot study in high burden district in South Africa. BMC Infect Dis 2018; 18:106.

33. McCreesh N, Faghmous I, Looker C, et al. Coverage of clinic-based TB screening in South Africa may be low in key risk groups. Public Health Action 2016; 6:19-21.

34. Sander MS, Laah SN, Titahong CN, et al. Systematic screening for tuberculosis among hospital outpatients in Cameroon: the role of screening and testing algorithms to improve case detection. J Clin Tuberc Other Mycobact Dis 2019; 15:100095.

35. Nguyen LH, Codlin AJ, Vo LNQ, et al. An evaluation of programmatic community-based chest X-ray screening for tuberculosis in Ho Chi Minh City, Vietnam. Trop Med Infect Dis 2020; 5:185.

36. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening—systematic screening for tuberculosis disease. Geneva, Switzerland: World Health Organization, 2021. Available at: https://www.who.int/publications/i/item/9789240022676. Accessed 6 October 2021.

37. Ramos A, Carvalho T, Guimarães JT. The importance of multiple samples in mycobacterial recovery: a 10-year retrospective study. Int J Mycobacteriology 2019; 8:175-9.

38. Islam MR, Khatun R, Khaja M, Uddin M, Khan SR. Yield of two consecutive sputum specimens for the effective diagnosis of pulmonary tuberculosis. PLoS One 2013; 8:8-11.